Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Identification of a novel gene signature predicting response to first-line chemotherapy in BRCA wild-type high-grade serous ovarian cancer patients

Fig. 3

a Morphology of primary HGSOC cell lines (scale bars 200 μm) and representative images of cytokeratin 7 immunohistochemical and immunofluorescence staining (scale bars 100 and 20 μm). b Waterfall plot for paclitaxel and cisplatin IC50 values (extracted from dose-response curves) of primary and established HGSOC cell lines. The steady state (Css) or the maximum in vivo plasma concentrations are indicated by the solid line (see Table S5). Bars above the solid line represent the resistant samples and bars below represent the sensitive samples. c) Polar bar plot of the 10 selected biomarkers. Ten biomarkers have been chosen from the intersection of the top-42 RNA-seq DEGs with BH-adjusted P-value less than 5E-03 and |log2FC| > 1 and HT RT-qPCR two-sided Wilcoxon rank sum test P value < 0.05. For each of them, the bar colour shading corresponds to the estimated resistant – sensitive shift, and the bar height corresponds to the number of evidences supporting their regulation (1: patients only; 2: patients and OV.GEM cell lines). The black dots show the -log10 of the Wilcoxon’s P-value (the further the distance from the center, the stronger the significance). The red circle corresponds to a P value of 0.05

Back to article page